You are not logged in
Visit our Twitter
Visit our LinkedIn
Dalcetrapib Advisory Board Meeting
If you wish to view the details for the meeting, then please click the button.
Back to the Meeting Details
1. In view of the 2018 and 2019 changes in the AHA/ACC and ESC/EAS guidelines respectively, what do you consider as the best post-ACS standard of care today?
2. Assuming a statistically significant dal-GenE study with at least 15% RRR on top of best standard of care, the concept of pharmacogenomic precision medicine will be new for cardiologists
2a. What excites you about the hypothesis DalCor is pursuing and the work conducted over the last 5 years?
2b. What causes hesitation regarding the hypothesis DalCor is pursuing and the work conducted over the last 5 years?
3. In light of other treatment options, where would you rank pharmacogenomic precision medicine (companion diagnostic blood test to identify the ADCY9 AA gene and dalcetrapib) in your post-ACS treatment strategies?
4. With approximately 20% of ACS patients having the ADCY9 AA genotype, what additional evidence would motivate you to prescribe this pharmacogenomic precision medicine?
5. What would you need for you to build awareness and understanding with your peers towards this pharmacogenomic precision medicine?
6. What lessons we should consider from other transformative therapies and approaches in cardiology?
COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally.
Disclaimer: The material and content contained in the website engage.cor2ed.com is for healthcare professionals only. Although every effort is made to ensure that the material within this website is accurate and timely, it is provided for informational and educational purposes only. The information provided is not intended as a substitute for medical professional help, advice, diagnosis or treatment and may not be applicable to every case or country.
© Copyright 2021 | All Rights Reserved